Collegeville, PA, United States of America

Feng Wang

This inventor holds 1 USPTO granted patent. Top assignee: Glaxosmithkline LLC. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Feng Wang. Retrieved from https://idiyas.com/inventor/feng-wang-s562xqhl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Feng Wang

Introduction

Feng Wang is an accomplished inventor based in Collegeville, PA (US). He has made significant contributions to the field of medical research, particularly in the development of novel therapeutic compounds.

Latest Patents

Feng Wang holds a patent for IL-8 receptor antagonists. This invention relates to novel compounds, compositions, and combinations thereof, which are useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). He has 1 patent to his name.

Career Highlights

Feng Wang is currently employed at GlaxoSmithKline LLC, where he continues to work on innovative solutions in the pharmaceutical industry. His research focuses on developing treatments that target specific disease mechanisms.

Collaborations

Feng has collaborated with notable colleagues, including Gregory L. Adams and James Brackley, III. These partnerships have enhanced his research and contributed to the advancement of medical science.

Conclusion

Feng Wang's work exemplifies the impact of innovation in healthcare, showcasing how targeted therapies can lead to significant advancements in treatment options. His contributions are vital to the ongoing efforts in medical research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…